Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants

Next Previous
X
Search
Trial Profile

A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ-64300535 (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 26 Jun 2022 Results from two clinical studies (64300535HPB1003 and 64300535HPB1001) reporting T cell responses and ELISpot responses over baseline to core and/or polymerase in Chronic Hepatitis B patients presented at The International Liver Congress 2022
    • 21 Dec 2021 Status changed from active, no longer recruiting to completed.
    • 03 Nov 2021 Planned primary completion date changed from 12 Oct 2021 to 7 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top